China SXT Pharmaceuticals Reports H1 2025 Financials
Ticker: SXTC · Form: 6-K · Filed: Dec 31, 2025 · CIK: 1723980
| Field | Detail |
|---|---|
| Company | China Sxt Pharmaceuticals, Inc. (SXTC) |
| Form Type | 6-K |
| Filed Date | Dec 31, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 6-K, foreign-private-issuer
TL;DR
SXT just dropped its Q2 and Q3 2025 financials, check 'em out.
AI Summary
China SXT Pharmaceuticals, Inc. filed a Form 6-K on December 31, 2025, to report its financial results for the six months ended September 30, 2025. The company, based in Taizhou, Jiangsu, China, is a foreign private issuer filing under the 1934 Act.
Why It Matters
This filing provides investors with updated financial performance data for China SXT Pharmaceuticals, crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- China SXT Pharmaceuticals, Inc. (company) — Registrant
- September 30, 2025 (date) — End of reporting period
- December 31, 2025 (date) — Filing date
- Taizhou, Jiangsu, China (location) — Company headquarters
FAQ
What period do the financial results in this 6-K cover?
The financial results cover the six months ended September 30, 2025.
What form is being filed?
A Form 6-K is being filed.
When was this Form 6-K filed?
This Form 6-K was filed as of December 31, 2025.
Where is China SXT Pharmaceuticals, Inc. located?
The company's principal executive office is located at 178 Taidong Rd North, Taizhou Jiangsu, China.
Is China SXT Pharmaceuticals, Inc. required to file annual reports on Form 20-F or 40-F?
The company indicates it files annual reports under cover of Form 20-F.
Filing Stats: 311 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2025-12-31 16:01:02
Filing Documents
- ea0270990-6k_chinasxt.htm (6-K) — 22KB
- ea027099001ex99-1_chinasxt.htm (EX-99.1) — 144KB
- ea027099001ex99-2_chinasxt.htm (EX-99.2) — 678KB
- ex99-1_001.jpg (GRAPHIC) — 60KB
- 0001213900-25-127097.txt ( ) — 6340KB
- sxtc-20250930.xsd (EX-101.SCH) — 64KB
- sxtc-20250930_cal.xml (EX-101.CAL) — 53KB
- sxtc-20250930_def.xml (EX-101.DEF) — 310KB
- sxtc-20250930_lab.xml (EX-101.LAB) — 546KB
- sxtc-20250930_pre.xml (EX-101.PRE) — 330KB
- ea0270990-6k_chinasxt_htm.xml (XML) — 720KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 99.2 Unaudited Condensed Consolidated Financial Statements for the six months ended September 30, 2025 and 2024 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: December 31, 2025 China SXT Pharmaceuticals, Inc. By: /s/ Feng Zhou Name: Feng Zhou Title: Co-Chief Executive Officer By: /s/ Simon Lim Sze Beng Name: Simon Lim Sze Beng Title: Co-Chief Executive Officer 3